

World Journal of *Diabetes*

World J Diabetes 2021 May 15; 12(5): 514-684



OPINION REVIEW

- 514 Euglycemic diabetic ketoacidosis: A missed diagnosis
Nasa P, Chaudhary S, Shrivastava PK, Singh A

REVIEW

- 524 New insights into renal lipid dysmetabolism in diabetic kidney disease
Mitrofanova A, Burke G, Merscher S, Fornoni A
- 541 Recent advances in new-onset diabetes mellitus after kidney transplantation
Montada-Atin T, Prasad GVR
- 556 Renal gluconeogenesis in insulin resistance: A culprit for hyperglycemia in diabetes
Sharma R, Tiwari S

MINIREVIEWS

- 569 Fear of hypoglycemia, a game changer during physical activity in type 1 diabetes mellitus patients
Cigrovski Berkovic M, Bilic-Curcic I, La Grasta Sabolic L, Mrzljak A, Cigrovski V
- 578 Chronic care model in the diabetes pay-for-performance program in Taiwan: Benefits, challenges and future directions
Chen TT, Oldenburg B, Hsueh YS
- 590 Advanced-glycation end-products axis: A contributor to the risk of severe illness from COVID-19 in diabetes patients
Rojas A, Lindner C, González I, Morales MA
- 603 Current advances in using tolerogenic dendritic cells as a therapeutic alternative in the treatment of type 1 diabetes
Ríos-Ríos WJ, Sosa-Luis SA, Torres-Aguilar H
- 616 Role of insulin and insulin resistance in androgen excess disorders
Unluhizarci K, Karaca Z, Kelestimur F
- 630 Impact of spiritual beliefs and faith-based interventions on diabetes management
Onyishi CN, Ilechukwu LC, Victor-Aigbodion V, Eseadi C
- 642 COVID-19 and hyperglycemia/diabetes
Michalakos K, Ilias I
- 651 Telemedicine in the COVID-19 era: Taking care of children with obesity and diabetes mellitus
Umamo GR, Di Sessa A, Guarino S, Gaudino G, Marzuillo P, Miraglia del Giudice E

ORIGINAL ARTICLE**Basic Study**

- 658** Diabetes-related intestinal region-specific thickening of ganglionic basement membrane and regionally decreased matrix metalloproteinase 9 expression in myenteric ganglia

Bódi N, Mezei D, Chakraborty P, Szalai Z, Barta BP, Balázs J, Rázga Z, Hermes E, Bagyánszki M

Observational Study

- 673** Relationships between emissions of toxic airborne molecules and type 1 diabetes incidence in children: An ecologic study

Di Ciaula A, Portincasa P

ABOUT COVER

Editorial Board Member of *World Journal of Diabetes*, Fernando Cordido, MD, PhD, Full Professor, Department of Medicine, University A Coruña, A Coruña 15006, Spain. Cordido.Carballido@sergas.es

AIMS AND SCOPE

The primary aim of *World Journal of Diabetes* (*WJD*, *World J Diabetes*) is to provide scholars and readers from various fields of diabetes with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJD mainly publishes articles reporting research results and findings obtained in the field of diabetes and covering a wide range of topics including risk factors for diabetes, diabetes complications, experimental diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes, diabetic angiopathies, diabetic cardiomyopathies, diabetic coma, diabetic ketoacidosis, diabetic nephropathies, diabetic neuropathies, Donohue syndrome, fetal macrosomia, and prediabetic state.

INDEXING/ABSTRACTING

The *WJD* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, and PubMed Central. The 2020 Edition of Journal Citation Reports® cites the 2019 impact factor (IF) for *WJD* as 3.247; IF without journal self cites: 3.222; Ranking: 70 among 143 journals in endocrinology and metabolism; and Quartile category: Q2.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Yan-Jie Ma*; Production Department Director: *Xiang Li*; Editorial Office Director: *Jia-Ping Yan*.

NAME OF JOURNAL

World Journal of Diabetes

ISSN

ISSN 1948-9358 (online)

LAUNCH DATE

June 15, 2010

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Timothy Koch

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-9358/editorialboard.htm>

PUBLICATION DATE

May 15, 2021

COPYRIGHT

© 2021 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Euglycemic diabetic ketoacidosis: A missed diagnosis

Prashant Nasa, Sandeep Chaudhary, Pavan Kumar Shrivastava, Aanchal Singh

ORCID number: Prashant Nasa 0000-0003-1948-4060; Sandeep Chaudhary 0000-0002-9295-5132; Pavan Kumar Shrivastava 0000-0001-6204-8710; Aanchal Singh 0000-0002-2234-9962.

Author contributions: Nasa P and Chaudhary S contributed equally to this work; Nasa P, Chaudhary S, Shrivastava PK and Singh A designed the research study; Nasa P and Chaudhary S searched and reviewed the literature; Nasa P conceptualized and designed the figure; All authors have read and approved the final manuscript.

Conflict-of-interest statement:

Prashant Nasa has received fees for serving as an advisory board member for Edward Life Sciences. Other authors declare no conflict of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Prashant Nasa, Aanchal Singh, Department of Critical Care Medicine, NMC Specialty Hospital, Dubai 7832, United Arab Emirates

Sandeep Chaudhary, Department of Endocrinology, NMC Specialty Hospital, Dubai 7832, United Arab Emirates

Pavan Kumar Shrivastava, Department of Internal Medicine, NMC Specialty Hospital, Dubai 7832, United Arab Emirates

Corresponding author: Prashant Nasa, MD, Head of the Department, Department of Critical Care Medicine, NMC Specialty Hospital, Al Nahda 2, Dubai 7832, United Arab Emirates. dr.prashantnasa@hotmail.com

Abstract

Euglycemic diabetic ketoacidosis (DKA) is an acute life-threatening metabolic emergency characterized by ketoacidosis and relatively lower blood glucose (less than 11 mmol/L). The absence of hyperglycemia is a conundrum for physicians in the emergency department and intensive care units; it may delay diagnosis and treatment causing worse outcomes. Euglycemic DKA is an uncommon diagnosis but can occur in patients with type 1 or type 2 diabetes mellitus. With the addition of sodium/ glucose cotransporter-2 inhibitors in diabetes mellitus management, euglycemic DKA incidence has increased. The other causes of euglycemic DKA include pregnancy, fasting, bariatric surgery, gastroparesis, insulin pump failure, cocaine intoxication, chronic liver disease and glycogen storage disease. The pathophysiology of euglycemic DKA involves a relative or absolute carbohydrate deficit, milder degree of insulin deficiency or resistance and increased glucagon/insulin ratio. Euglycemic DKA is a diagnosis of exclusion and should be considered in the differential diagnosis of a sick patient with a history of diabetes mellitus despite lower blood glucose or absent urine ketones. The diagnostic workup includes arterial blood gas for metabolic acidosis, serum ketones and exclusion of other causes of high anion gap metabolic acidosis. Euglycemic DKA treatment is on the same principles as for DKA with correction of dehydration, electrolytes deficit and insulin replacement. The dextrose-containing fluids should accompany intravenous insulin to correct metabolic acidosis, ketonemia and to avoid hypoglycemia.

Key Words: Diabetic Ketoacidosis; Sodium/glucose co-transporter-2 inhibitors; Pregnancy with diabetic ketoacidosis; Diabetes complications; Pregnancy in diabetes; Ketosis; Metabolic acidosis

Manuscript source: Invited manuscript

Specialty type: Endocrinology and metabolism

Country/Territory of origin: United Arab Emirates

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

Received: January 22, 2021

Peer-review started: January 22, 2021

First decision: February 25, 2021

Revised: March 1, 2021

Accepted: March 25, 2021

Article in press: March 25, 2021

Published online: May 15, 2021

P-Reviewer: Patoulas DI

S-Editor: Zhang L

L-Editor: Filipodia

P-Editor: Ma YJ



©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Euglycemia diabetic ketoacidosis (DKA) is an uncommon, life-threatening emergency with lower normal blood glucose. Euglycemic DKA can occur in both types of diabetes mellitus, and the absence of hyperglycemia may delay diagnosis with worse outcomes. The use of sodium/glucose cotransporter-2 (SGLT-2) inhibitors as a therapeutic option in the management of diabetes mellitus has increased the incidence of euglycemic DKA. Euglycemic DKA should be considered in any unexplained metabolic acidosis with a history of diabetes mellitus and associated risk factors. Patients on SGLT-2 inhibitors must be educated about potential risk factors for euglycemic DKA and dose adjustment for sick days.

Citation: Nasa P, Chaudhary S, Shrivastava PK, Singh A. Euglycemic diabetic ketoacidosis: A missed diagnosis. *World J Diabetes* 2021; 12(5): 514-523

URL: <https://www.wjgnet.com/1948-9358/full/v12/i5/514.htm>

DOI: <https://dx.doi.org/10.4239/wjcd.v12.i5.514>

INTRODUCTION

Diabetic ketoacidosis (DKA) is widely known as a life-threatening acute complication of diabetes mellitus (DM). It mainly occurs in patients with type 1 DM; however, any acute illness like infection, trauma or acute coronary syndrome may also trigger DKA in type 2 DM. Hyperglycemia (plasma glucose > 14 mmol/L) is a hallmark in the diagnosis of DKA completing the triad with metabolic acidosis and ketonemia[1,2].

Euglycemic DKA is defined as ketoacidosis (pH < 7.3 or serum bicarbonate < 18 mmol/L) with either near-normal plasma glucose or a milder degree of hyperglycemia (11-14 mmol/L)[3,4]. The absence of hyperglycemia can conceal the underlying DKA creating a diagnostic dilemma especially in the emergency department, which is associated with worse outcomes[3-5]. Dehydration in euglycemic DKA is also minor in the absence of polyuria and polydipsia. Patients may present instead with malaise, anorexia and tachypnoea because of ketonemia and accompanying ketoacidosis. The high index of suspicion with early testing for metabolic acidosis and blood ketones can identify these patients[4].

Euglycemic DKA was first described in 1973 by Munro *et al*[6] among type 1 DM. Euglycemic DKA is an uncommon diagnosis with an incidence ranging between 2.6% to 3.2% of admissions with DKA[7,8]. In a study by Munro *et al*[6], the incidence of euglycemic DKA had an incidence of 3.2%, using a plasma glucose cut-off of less than 16.7 mmol/L[8]. However, the cut-off of plasma glucose used for euglycemic DKA in recent reviews is lower (either 14 mmol/L[3] or 11 mmol/L[4]). Authors have also used other terminology for euglycemia, like near-normal or lower than anticipated plasma glucose[9,10]. The true incidence of euglycemic DKA is therefore unknown. With the introduction of sodium/glucose cotransporter-2 (SGLT-2) inhibitors in DM management, there is a definitive increase in the published case reports or series on euglycemic DKA[9,11]. The other common causes of euglycemic DKA are pregnancy and prolonged fasting. In this review, we will discuss the pathophysiology, diagnostic considerations and management of euglycemic DKA.

PATHOPHYSIOLOGY OF EUGLYCEMIC DKA

The pathophysiology of DKA is already very well-known, characterized by a relative or absolute deficiency of insulin and excess of counterregulatory (or counter responsive) hormones like glucagon, corticosteroids, catecholamines or growth hormones[1]. The hormonal imbalance causes hyperglycemia by increasing glycogenolysis, hepatic gluconeogenesis and decreased peripheral utilization of glucose. It also promotes gluconeogenesis and ketogenesis from free fatty acid mobilization by lipolysis in adipose tissue and proteolysis of amino acids[1]. Ketone bodies (beta-hydroxybutyrate, acetoacetate and acetone) are responsible for metabolic acidosis, while hyperglycemia through glycosuria and osmotic diuresis causes dehydration and

hypovolemia (Figure 1).

Carbohydrate deficit has a pivotal role in the pathophysiology of euglycemic DKA, while insulin deficit or insulin resistance is relatively minor and secondary (Figure 1B). However, the counterregulatory hormone production is unabated, causing an increased glucagon/insulin ratio and triggering ketogenesis with no significant change in hepatic gluconeogenesis and peripheral glucose utilization[3,4,12]. The precipitating causes for euglycemic DKA include fasting or prolonged physical activity with depleted hepatic glycogen stores and hence impaired glycogenolysis[3,12]. Increased glucagon also promotes lipid oxidation, generating acetyl-CoA and ketone bodies when glycolysis intermediates are unavailable due to reduced intracellular glucose oxidation. The unabated ketonemia and glycosuria (seen usually with SGLT-2 inhibitors) contribute to euglycemic (or hypoglycemic) DKA[4,9].

The three common causes of euglycemic DKA are SGLT-2 inhibitors, pregnancy and prolonged fasting.

SGLT-2 inhibitors

SGLT-2 inhibitors are the latest group of medications added to the arsenal to treat patients with DM. Their promotion in type 2 DM is due to clinical trials suggesting protection against major adverse cardiovascular events and reduced hospitalization for heart failure and deaths[13]. SGLT-2 inhibitors have also been shown to slow chronic kidney disease progression in type 2 DM[14,15]. The added advantages appeared to be modest weight reduction and lower systolic blood pressure aside from its effect on hyperglycemia[13,15]. SGLT-2 inhibitors act by blocking the SGLT-2 cotransporter located in the early proximal renal tubule, which is responsible for the reabsorption of most (80%-90%) of the glucose filtered by the glomerulus. It leads to glucosuria and resultant lowering of blood plasma glucose concentration[16,17]. The exact mechanism that can precipitate DKA in susceptible individuals includes, osmotic diuresis along with glucosuria (causing a state of carbohydrate deficit), volume depletion and dehydration[9,16]. Carbohydrate deficit and hypovolemia promote glucagon release, increase glucagon/insulin ratio and trigger ketogenesis with euglycemia. The other factors include the direct effect of SGLT-2 inhibitors on pancreatic alpha cells, causing glucagon release and inhibiting ketone bodies excretion by the kidneys[18,19].

There has been a steady increase in the published reports on DKA with the growing use of SGLT-2 inhibitors[9]. The exact incidence rate of SGLT-2 inhibitors associated with DKA is unknown. The clinical trials of SGLT-2 inhibitors with type 2 DM have reported an incidence of 0.16 to 0.76 events per 1000 patient-years[9,20]. In a sizeable multicentric cohort study by the Canadian Network for Observational Drug Effect Studies, the incidence of DKA with SGLT-2 inhibitors in type 2 DM was 1.40 (1.29-1.53) per 1000 patient-years. The risk of DKA was nearly three-fold higher with SGLT-2 inhibitors than dipeptidyl peptidase-4 inhibitors. The increased risk of DKA was observed with all three SGLT-2 inhibitors suggesting a class effect, with canagliflozin (hazard ratio 3.58) having the highest risk[21]. In an analysis of the Food and Drug Administration's adverse event reporting system on DKA incidence with SGLT-2 inhibitors, there was a seven-fold increased risk, and around two-thirds of the reported DKA cases were euglycemic[22]. The risk is higher in patients with significant insulin insufficiency or type 1 DM (up to 9%)[9,16].

The United States Food and Drug Administration has warned against the risk of DKA with SGLT-2 inhibitors and so far has not approved its use for type 1 DM[23]. The risk of DKA with SGLT-2 inhibitors in type 1 DM varies widely across the published data of different randomized controlled trials, and factors responsible for such variation are not well understood. In a trial of dapagliflozin evaluation in patients with inadequately controlled type 1 diabetes[24], a significant number of patients in the dapagliflozin groups had DKA as compared to placebo at 52 weeks of follow-up. The risk of DKA was 4.0%, 3.4% and 1.9% in the dapagliflozin 5 mg, 10 mg and placebo groups, respectively. The DKA rate was also higher in the empagliflozin 10 mg and 25 mg groups compared with placebo in the empagliflozin as adjunctive to insulin therapy program[24]. The DKA rate was 4.3% and 3.3% with empagliflozin 25 mg and 10 mg groups, respectively, compared to 1.2% in the placebo group. It corresponds to an incidence of 5.9, 5.1 and 1.8 per 1000 patient-years[25], respectively. A similar rate of DKA has been observed in clinical trials of sotagliflozin and canagliflozin[26,27].

The duration of SGLT-2 inhibitor treatment before a diagnosis of DKA onset is hugely variable in the literature (0.3-420 days)[28]. In a recent meta-analysis by Musso *et al*[29], the risk factors of DKA with SGLT-2 inhibitors in type 1 DM included (1) baseline body mass index > 27 kg/m²; (2) insulin resistance calculated by estimated




Figure 1 Ketone bodies (beta-hydroxybutyrate, acetoacetate and acetone) are responsible for metabolic acidosis, while hyperglycemia through glycosuria and osmotic diuresis causes dehydration and hypovolemia. A: Pathophysiology of diabetic ketoacidosis; B: Pathophysiology of euglycemic diabetic ketoacidosis. FFA: Free fatty acids; ↑: Increase; ↓: Decrease; ~: No change.

glucose disposal rate < 8.3 mg/kg/min; (3) the ratio of total insulin dose reduction-to-baseline insulin sensitivity; and (4) degree of volume depletion. These risk factors should be considered by clinicians while using SGLT-2 inhibitors in type 1 DM to reduce the risk of DKA. Recently, the National Institute for Health and Care Excellence revised its guidance and recommended SGLT-2 inhibitors for the treatment of type 1 DM[30]. The patients with a body mass index of 27 kg/m² or more, insulin requirement of 0.5 units/kg of body weight/day or more and inadequate glycemic control despite optimal insulin therapy can be considered for the addition of dapagliflozin with insulin under supervision of a physician. However, the patient should receive education on the risk, signs and symptoms of DKA. They should also be trained on home monitoring of blood ketones and on appropriate action-plan in case of elevated blood ketones[30].

DKA in patients on SGLT-2 inhibitors can be precipitated by one of these causes (Table 1). The excessive reduction (> 50%) or omission of insulin doses, insulin pump failure or malfunction, a low carbohydrate diet, nausea and vomiting induced by other drug combination like glucagon-like peptide 1 agonists, excessive alcohol intake, acute stressful conditions like myocardial infarction, heart failure, infections or fever, trauma and surgery[9,10]. The SGLT-2 inhibitor prescription in a new-onset DM without establishing the mechanism of hyperglycemia can also precipitate DKA in undiagnosed type 1 DM[28].

Pregnancy

DKA incidence in pregnancy is significantly higher than in nonpregnant females (8.9% vs 3.1%) and associated with lower blood glucose levels and increased perinatal morbidity and mortality[31,32]. There are various case reports of euglycemic DKA in pregnancy with type 1 DM, type 2 DM and gestational DM[32-36]. The physiological changes of pregnancy include hypoinsulinemia and carbohydrate deficit to match the glucose requirement of the fetus and placenta[31,35,36]. The respiratory alkalosis seen with pregnancy and compensatory urinary loss of bicarbonate reduces the body reserves to buffer metabolic acidosis. There is also an insulin resistance caused by counter-regulatory pregnancy hormones (progesterone, estrogen, human placental lactogen and tumor necrosis factor- α) seen during the second and third trimester of pregnancy. Euglycemia DKA is also common during pregnancy due to physiological hemodilution of blood glucose and increased glomerular filtration rate with

Table 1 Precipitating causes for euglycemic diabetic ketoacidosis and their mechanisms

Risk factors	Pathophysiology
Infection	Insulin resistance due to counterregulatory hormones (adrenaline, glucagon, <i>etc.</i>), increased peripheral glucose utilization, decreased intake (nausea, vomiting)
Surgery	Perioperative fasting, gastrointestinal surgery has increased incidence as fasting is prolonged and/or gut absorption is slow
Fasting	Decreased glycogen stores, increased risk with SGLT-2 inhibitors and type 1 DM
Alcohol intake	Decreased carbohydrate intake, osmotic diuresis, increased ketogenesis (beta hydroxybutyrate) due to altered NADH/NAD ratio, increased risk in patients on SGLT-2 inhibitors
Acute vascular events (ACS or stroke)	Increased counterregulatory hormones, decreased oral intake
Trauma	Decreased oral intake, increased counterregulatory hormone, blood glucose dilution by large fluid shifts during resuscitation
Prolonged physical activity or exercise	Increased counterregulatory hormones, increased peripheral glucose utilization, decreased carbohydrate intake

ACS: Acute coronary syndrome; DM: Diabetes mellitus; NAD: Nicotinamide adenine dinucleotide; NADH: Nicotinamide adenine dinucleotide hydrogen; SGLT2: Sodium/glucose cotransporter-2.

glucosuria[31,35,36]. Any acute illness like infection, vomiting, fasting or short starvation can trigger ketogenesis in pregnancy. Ketogenesis and metabolic acidosis during pregnancy occur faster than when not pregnant and at lower blood sugar levels[31,35,36]. Any unexplained acidosis with a history of nausea, vomiting and decreased intake in a pregnant should raise a suspicion of euglycemic DKA[4].

Fasting

Low-calorie intake, especially with intercurrent illness in patients with type 2 DM, can precipitate DKA with euglycemia[37,38]. Patients with type 1 DM who do not adjust their insulin to low carbohydrate intake while fasting or ill can also develop euglycemic DKA[38,39]. Fasting produces a carbohydrate deficit and depletion of glycogen stores leading to alternative energy sources like free fatty acids and lipolysis[39]. Continued intake of insulin and depleted glycogen stores maintain a euglycemic state while lipolysis and ketogenesis remain unabated, triggering euglycemic DKA. A very restricted carbohydrate diet or starvation can also cause euglycemic DKA in patients without DM[4]. The fasting-induced euglycemic DKA must be differentiated from starvation ketosis in which metabolic acidosis is not present (serum bicarbonate > 18 mmol/L)[4,40]. However, euglycemic DKA during fasting or starvation is familiar with type 1 DM *vs* nondiabetic patients.

The keto diet, characterized by a low carbohydrate and high fat diet, is promoted as a popular weight-loss method and other physical or metabolic benefits[41,42]. The carbohydrate deficit and excess of fatty acids promote ketogenesis and divert ketones bodies as a source of nutrition. The weight loss is caused by reduced insulin requirement, ketone-induced osmotic diuresis and decreased oral intake because of ketonemia. The keto diet has been tried effectively in type 2 DM with weight loss benefits, better glycemic control and medication reduction for a short duration[42-45]. The benefit is found more in patients with obesity and rigorous compliance with the diet. However, the long-term effects on glycemic control, adherence and safety in patients with DM are unproven[45]. The keto diet can precipitate DKA in type 2 DM, especially during pregnancy or SGLT-2 inhibitors with a higher incidence of euglycemic DKA[44-49]. The safety of the keto diet has not been demonstrated in type 1 DM due to the risk of ketonemia and hypoglycemia[42,50].

Other causes

Euglycemic DKA has been rarely reported with other conditions like bariatric surgery[51-53], acute pancreatitis[54], sepsis[36,55], cocaine intoxication[56], insulin pump failure[56] and gastroparesis[57]. The patients undergoing bariatric surgery are prone to DKA because of perioperative deficient carbohydrate diet and prolonged fasting[4,53]. Euglycemic DKA risk is higher in type 1 DM, patients on SGLT-2 inhibitors and prolonged perioperative fasting during bariatric surgery[51,52]. Exogenous insulin administration in patients with DKA while en route to the hospital can also present lower blood glucose on admission[1].

DIAGNOSIS

Euglycemic DKA is an acute life-threatening medical emergency. The absence of hyperglycemia delays euglycemic DKA diagnosis in the emergency department or intensive care unit[3,4]. However, euglycemic DKA is a diagnosis of exclusion, and other causes of high anion gap metabolic acidosis must be excluded[3]. The common causes of high anion gap metabolic acidosis are alcoholic intoxication (excessive ethanol or toxic alcohols like methanol or polyethylene glycol), sepsis, lactic acidosis, drug overdoses (salicylate and tricyclic antidepressants) and renal failure. Other differential diagnoses include alcoholic ketoacidosis, chronic liver disease, starvation ketosis and glycogen storage disease.

Alcoholic ketoacidosis is seen in patients with chronic alcoholism[3,7]. The patient is in a state of chronic carbohydrate deficit and is dependent on alcohol for calories. Any acute illness that can cause an inability to consume alcohol triggers ketonemia and ketoacidosis. The presentation is similar to euglycemic DKA with gastrointestinal symptoms (nausea, vomiting or abdominal pain), metabolic acidosis and ketonemia. Some authors consider alcoholic ketoacidosis as a subtype of euglycemic DKA[3,7]. The pathophysiology is also similar with an increased glucagon/insulin ratio. However, a history of binge alcohol consumption, nondiabetic and hypoglycemia instead of euglycemia helps diagnose alcoholic ketoacidosis[58]. The ketone bodies in alcoholic ketoacidosis are predominantly β -hydroxybutyrate (instead of acetoacetate), which could not be detected on routine urine strip testing[59]. Serum ketones must be used for detection of ketonemia in the cases of suspicion of alcoholic ketoacidosis.

Euglycemic ketoacidosis because of either fasting or any intercurrent illness with reduced calorie intake needs to be differentiated from starvation ketosis[4,40]. No previous history of DM, no intercurrent illness and hypoglycemia differentiate starvation ketosis. The metabolic acidosis is also not profound, with bicarbonate levels usually more than 18 mmol/L.

Sepsis[36,55] with or without associated lactic acidosis is a common presentation in an emergency that can conceal euglycemic DKA. High lactate levels with the absence of serum ketones help in the diagnosis of sepsis.

Unexplained high anion gap metabolic acidosis in a patient with DM and associated risk factors should raise suspicion of euglycemic DKA. A detailed history of risk factors like pregnancy, surgery, fasting, infections and SGLT-2 inhibitors should be evaluated (Table 1). The laboratory tests include serum and urine ketones, electrolytes (including calcium and magnesium), glucose, renal function (creatinine, blood urea nitrogen), blood gas analysis (venous or arterial), lactic acid, chest radiograph and electrocardiogram. Wide osmolar gap (the difference between measured and calculated serum osmolality), inebriate state and multiorgan involvement help to diagnose toxic alcohol ingestion. History and symptoms of infection with laboratory tests showing leukocytosis, procalcitonin, organ dysfunction and lactate help diagnose sepsis and septic shock.

TREATMENT

The treatment is straightforward once the diagnosis is made. The treatment is based on the same principles as in DKA[1]: Insulin to correct metabolic acidosis and anion gap and correction of electrolytes and dehydration. The fluid resuscitation is similar to DKA with correction of dehydration and starts with balanced crystalloids. Insulin replacement using a fixed rate intravenous insulin infusion calculated on 0.1 units/per kilogram body weight should be continued until anion gap (metabolic acidosis) correction, and the patient can accept orally. However, an early glucose requirement (for prevention of hypoglycemia) allows concomitant insulin infusion to suppress ketogenesis[3]. Dextrose (10% or 5%) and intravenous infusion of insulin must be used until the anion gap and metabolic acidosis is corrected. The resolution of DKA is defined as pH > 7.3 units, bicarbonate > 15.0 mmol/L and blood ketone level < 0.6 mmol/L[1]. Patients may require intensive care unit admission and monitoring for hemodynamic and electrolyte disturbances. The laboratory monitoring for acidosis, glucose and electrolytes must be similar to DKA management.

PREVENTION OF EUGLYCEMIC DKA

The patients who are prescribed SGLT-2 inhibitors should be explained the risk factors of DKA (Table 1). The off-label use of SGLT-2 inhibitors in type 1 DM should be done with close monitoring, starting with a lower dose, personalized insulin reduction regimen and patient education on carbohydrate intake[9,10]. Patient education on “sick days” and other lifestyle modifications are essential and should be done in patients with type 1 and type 2 DM[9]. Education about stopping SGLT-2 inhibitors when feeling ill or feverish, prolonged exercise, fasting or excessive alcohol intake must be done. The drug should also be stopped 3-4 days before planned surgery and adjust the insulin regimen accordingly[9,10].

CONCLUSION

Euglycemic DKA can be a missed diagnosis in the emergency department with worse outcomes. The presence of metabolic acidosis in a patient with DM and risk factors should be assessed for ketonemia, even in the absence of hyperglycemia. Patients on SGLT-2 inhibitors must be educated about risk factors and dose adjustment for sick days.

REFERENCES

- 1 **Kitabchi AE**, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. *Diabetes Care* 2009; **32**: 1335-1343 [PMID: 19564476 DOI: 10.2337/dc09-9032]
- 2 **Islam T**, Sherani K, Surani S, Vakil A. Guidelines and controversies in the management of diabetic ketoacidosis - A mini-review. *World J Diabetes* 2018; **9**: 226-229 [PMID: 30588284 DOI: 10.4239/wjd.v9.i12.226]
- 3 **Modi A**, Agrawal A, Morgan F. Euglycemic Diabetic Ketoacidosis: A Review. *Curr Diabetes Rev* 2017; **13**: 315-321 [PMID: 27097605 DOI: 10.2174/1573399812666160421121307]
- 4 **Barski L**, Eshkoli T, Brandstaetter E, Jotkowitz A. Euglycemic diabetic ketoacidosis. *Eur J Intern Med* 2019; **63**: 9-14 [PMID: 30910328 DOI: 10.1016/j.ejim.2019.03.014]
- 5 **Plewa MC**, Bryant M, King-Thiele R. Euglycemic Diabetic Ketoacidosis 2021 [PMID: 32119457]
- 6 **Munro JF**, Campbell IW, McCuish AC, Duncan LJ. Euglycaemic diabetic ketoacidosis. *Br Med J* 1973; **2**: 578-580 [PMID: 4197425 DOI: 10.1136/bmj.2.5866.578]
- 7 **Yu X**, Zhang S, Zhang L. Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis. *Int J Endocrinol* 2018; **2018**: 7074868 [PMID: 30369948 DOI: 10.1155/2018/7074868]
- 8 **Jenkins D**, Close CF, Krentz AJ, Nattrass M, Wright AD. Euglycaemic diabetic ketoacidosis: does it exist? *Acta Diabetol* 1993; **30**: 251-253 [PMID: 8180418 DOI: 10.1007/BF00569937]
- 9 **Goldenberg RM**, Berard LD, Cheng AYY, Gilbert JD, Verma S, Woo VC, Yale JF. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis. *Clin Ther* 2016; **38**: 2654-2664. e1 [PMID: 28003053 DOI: 10.1016/j.clinthera.2016.11.002]
- 10 **Handelsman Y**, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, Ferrannini E, Fonseca VA, Garber AJ, Grunberger G, LeRoith D, Umpierrez GE, Weir MR. American association of clinical endocrinologists and american college of endocrinology position statement on the association of sgl-2 inhibitors and diabetic ketoacidosis. *Endocr Pract* 2016; **22**: 753-762 [PMID: 27082665 DOI: 10.4158/EP161292.PS]
- 11 **Burke KR**, Schumacher CA, Harpe SE. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature. *Pharmacotherapy* 2017; **37**: 187-194 [PMID: 27931088 DOI: 10.1002/phar.1881]
- 12 **Bonora BM**, Avogaro A, Fadini GP. Euglycemic Ketoacidosis. *Curr Diab Rep* 2020; **20**: 25 [PMID: 32424730 DOI: 10.1007/s11892-020-01307-x]
- 13 **Zelniker TA**, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet* 2019; **393**: 31-39 [PMID: 30424892 DOI: 10.1016/S0140-6736(18)32590-X]
- 14 **Neuen BL**, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, Mahaffey KW, Charytan DM, Wheeler DC, Arnott C, Bompont S, Levin A, Jardine MJ. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol* 2019; **7**: 845-854 [PMID: 31495651 DOI: 10.1016/S2213-8587(19)30256-6]
- 15 **Toyama T**, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ, Heerspink HL, Wong MG, Ninomiya T, Wada T, Perkovic V. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-

- analysis. *Diabetes Obes Metab* 2019; **21**: 1237-1250 [PMID: 30697905 DOI: 10.1111/dom.13648]
- 16 **Peters AL**, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. *Diabetes Care* 2015; **38**: 1687-1693 [PMID: 26078479 DOI: 10.2337/dc15-0843]
 - 17 **Packer M**. SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action. *Diabetes Care* 2020; **43**: 508-511 [PMID: 32079684 DOI: 10.2337/dc19-0074]
 - 18 **Ferrannini E**, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle HJ. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. *J Clin Invest* 2014; **124**: 499-508 [PMID: 24463454 DOI: 10.1172/JCI172227]
 - 19 **Bonner C**, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J, Beaucamps C, Delalleau N, Popescu I, Malaisse WJ, Sener A, Deprez B, Abderrahmani A, Staels B, Pattou F. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. *Nat Med* 2015; **21**: 512-517 [PMID: 25894829 DOI: 10.1038/nm.3828]
 - 20 **Erondu N**, Desai M, Ways K, Meininger G. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. *Diabetes Care* 2015; **38**: 1680-1686 [PMID: 26203064 DOI: 10.2337/dc15-1251]
 - 21 **Douros A**, Lix LM, Fralick M, Dell'Aniello S, Shah BR, Ronksley PE, Tremblay É, Hu N, Alessi-Severini S, Fisher A, Bugden SC, Ernst P, Filion KB. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis: A Multicenter Cohort Study. *Ann Intern Med* 2020; **173**: 417-425 [PMID: 32716707 DOI: 10.7326/M20-0289]
 - 22 **Blau JE**, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. *Diabetes Metab Res Rev* 2017; **33** [PMID: 28736981 DOI: 10.1002/dmrr.2924]
 - 23 **Food and Drug Administration**. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. December 2015 [cited 17 January 2021]. Available from: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious>
 - 24 **Dandona P**, Mathieu C, Phillip M, Hansen L, Tschöpe D, Thorén F, Xu J, Langkilde AM; DEPICT-1 Investigators. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. *Diabetes Care* 2018; **41**: 2552-2559 [PMID: 30352894 DOI: 10.2337/dc18-1087]
 - 25 **Rosenstock J**, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, Zinman B, Skyler JS, George J, Soleymanlou N, Perkins BA. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. *Diabetes Care* 2018; **41**: 2560-2569 [PMID: 30287422 DOI: 10.2337/dc18-1749]
 - 26 **Sands AT**, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, Buse JB, Banks P, Heptulla R, Rendell M, Cefalu WT, Strumph P. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. *Diabetes Care* 2015; **38**: 1181-1188 [PMID: 26049551 DOI: 10.2337/dc14-2806]
 - 27 **Henry RR**, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. *Diabetes Care* 2015; **38**: 2258-2265 [PMID: 26486192 DOI: 10.2337/dc15-1730]
 - 28 **Bonora BM**, Avogaro A, Fadini GP. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature. *Diabetes Obes Metab* 2018; **20**: 25-33 [PMID: 28517913 DOI: 10.1111/dom.13012]
 - 29 **Musso G**, Sircana A, Saba F, Cassader M, Gambino R. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression. *PLoS Med* 2020; **17**: e1003461 [PMID: 33373368 DOI: 10.1371/journal.pmed.1003461]
 - 30 **National Institute for Health and Care Excellence (NICE) Guidance**. Dapagliflozin with insulin for treating type 1 diabetes. Technology appraisal guidance [TA597]. 28 August 2019 [cited 28 February 2021]. Available from: <https://www.nice.org.uk/guidance/ta597/chapter/1-Recommendations>
 - 31 **Sibai BM**, Viteri OA. Diabetic ketoacidosis in pregnancy. *Obstet Gynecol* 2014; **123**: 167-178 [PMID: 24463678 DOI: 10.1097/AOG.0000000000000060]
 - 32 **Guo RX**, Yang LZ, Li LX, Zhao XP. Diabetic ketoacidosis in pregnancy tends to occur at lower blood glucose levels: case-control study and a case report of euglycemic diabetic ketoacidosis in pregnancy. *J Obstet Gynaecol Res* 2008; **34**: 324-330 [PMID: 18588610 DOI: 10.1111/j.1447-0756.2008.00720.x]
 - 33 **Jaber JF**, Standley M, Reddy R. Euglycemic Diabetic Ketoacidosis in Pregnancy: A Case Report and Review of Current Literature. *Case Rep Crit Care* 2019; **2019**: 8769714 [PMID: 31531246 DOI: 10.1155/2019/8769714]
 - 34 **Madaan M**, Aggarwal K, Sharma R, Trivedi SS. Diabetic ketoacidosis occurring with lower blood glucose levels in pregnancy: a report of two cases. *J Reprod Med* 2012; **57**: 452-455 [PMID: 23091997]
 - 35 **Karpate SJ**, Morsi H, Shehmar M, Dale J, Patel C. Euglycemic ketoacidosis in pregnancy and its

- management: case report and review of literature. *Eur J Obstet Gynecol Reprod Biol* 2013; **171**: 386-387 [PMID: 24183348 DOI: 10.1016/j.ejogrb.2013.09.034]
- 36 **Lucero P**, Chapela S. Euglycemic Diabetic Ketoacidosis in the ICU: 3 Case Reports and Review of Literature. *Case Rep Crit Care* 2018; **2018**: 1747850 [PMID: 30364093 DOI: 10.1155/2018/1747850]
- 37 **Joseph F**, Anderson L, Goenka N, Vora J. Starvation-induced true diabetic euglycemic ketoacidosis in severe depression. *J Gen Intern Med* 2009; **24**: 129-131 [PMID: 18975036 DOI: 10.1007/s11606-008-0829-0]
- 38 **Burge MR**, Hardy KJ, Schade DS. Short-term fasting is a mechanism for the development of euglycemic ketoacidosis during periods of insulin deficiency. *J Clin Endocrinol Metab* 1993; **76**: 1192-1198 [PMID: 8496310 DOI: 10.1210/jcem.76.5.8496310]
- 39 **Burge MR**, Garcia N, Qualls CR, Schade DS. Differential effects of fasting and dehydration in the pathogenesis of diabetic ketoacidosis. *Metabolism* 2001; **50**: 171-177 [PMID: 11229425 DOI: 10.1053/meta.2001.20194]
- 40 **Larroumet A**, Camoin M, Foussard N, Alexandre L, Mesli S, Redonnet I, Baillet-Blanco L, Rigalleau V, Mohammedi K. Euglycemic ketoacidosis induced by therapeutic fasting in a non-diabetic patient. *Nutrition* 2020; **72**: 110668 [PMID: 31982728 DOI: 10.1016/j.nut.2019.110668]
- 41 **Mohorko N**, Černelič-Bizjak M, Poklar-Vatovec T, Grom G, Kenig S, Petelin A, Jenko-Pražnikar Z. Weight loss, improved physical performance, cognitive function, eating behavior, and metabolic profile in a 12-week ketogenic diet in obese adults. *Nutr Res* 2019; **62**: 64-77 [PMID: 30803508 DOI: 10.1016/j.nutres.2018.11.007]
- 42 **Bolla AM**, Caretto A, Laurenzi A, Scavini M, Piemonti L. Low-Carb and Ketogenic Diets in Type 1 and Type 2 Diabetes. *Nutrients* 2019; **11** [PMID: 31035514 DOI: 10.3390/nu11050962]
- 43 **Goday A**, Bellido D, Sajoux I, Crujeiras AB, Burguera B, García-Luna PP, Oleaga A, Moreno B, Casanueva FF. Short-term safety, tolerability and efficacy of a very low-calorie-ketogenic diet interventional weight loss program vs hypocaloric diet in patients with type 2 diabetes mellitus. *Nutr Diabetes* 2016; **6**: e230 [PMID: 27643725 DOI: 10.1038/nutd.2016.36]
- 44 **Saslow LR**, Kim S, Daubenmier JJ, Moskowitz JT, Phinney SD, Goldman V, Murphy EJ, Cox RM, Moran P, Hecht FM. A randomized pilot trial of a moderate carbohydrate diet compared to a very low carbohydrate diet in overweight or obese individuals with type 2 diabetes mellitus or prediabetes. *PLoS One* 2014; **9**: e91027 [PMID: 24717684 DOI: 10.1371/journal.pone.0091027]
- 45 **Sainsbury E**, Kizirian NV, Partridge SR, Gill T, Colagiuri S, Gibson AA. Effect of dietary carbohydrate restriction on glycemic control in adults with diabetes: A systematic review and meta-analysis. *Diabetes Res Clin Pract* 2018; **139**: 239-252 [PMID: 29522789 DOI: 10.1016/j.diabres.2018.02.026]
- 46 **Shaikh S**, Mohamed MM, Mujeeb A, Shaikh F, Harris B. Euglycemic Diabetic Ketoacidosis Precipitated by a Keto Diet: Importance of Dietary History in Diagnosis. *Cureus* 2020; **12**: e10199 [PMID: 33033677 DOI: 10.7759/cureus.10199]
- 47 **Fukuyama Y**, Numata K, Yoshino K, Santanda T, Funakoshi H. Euglycemic diabetic ketoacidosis due to a strict low-carbohydrate diet during treatment with sodium-glucose cotransporter 2 inhibitors. *Acute Med Surg* 2020; **7**: e480 [PMID: 31988792 DOI: 10.1002/ams2.480]
- 48 **Garay PS**, Zuniga G, Lichtenberg R. A Case of Euglycemic Diabetic Ketoacidosis Triggered by a Ketogenic Diet in a Patient With Type 2 Diabetes Using a Sodium-Glucose Cotransporter 2 Inhibitor. *Clin Diabetes* 2020; **38**: 204-207 [PMID: 32327896 DOI: 10.2337/cd19-0055]
- 49 **Yaron M**, Shalit R, Kreiser D, Cukierman-Yaffe T, Yoeli R. Very restricted carbohydrate (ketogenic) diet: A rare cause of a recurrent hypoglycemic-euglycemic diabetic ketoacidosis in the pregnancy. *Eur J Obstet Gynecol Reprod Biol* 2020; **248**: 257-258 [PMID: 32171603 DOI: 10.1016/j.ejogrb.2020.03.021]
- 50 **McClean AM**, Montorio L, McLaughlin D, McGovern S, Flanagan N. Can a ketogenic diet be safely used to improve glycaemic control in a child with type 1 diabetes? *Arch Dis Child* 2019; **104**: 501-504 [PMID: 30470684 DOI: 10.1136/archdischild-2018-314973]
- 51 **Dowsett J**, Humphreys R, Kronen R. Normal Blood Glucose and High Blood Ketones in a Critically Unwell Patient with T1DM Post-Bariatric Surgery: a Case of Euglycemic Diabetic Ketoacidosis. *Obes Surg* 2019; **29**: 347-349 [PMID: 30328578 DOI: 10.1007/s11695-018-3548-6]
- 52 **Iqbal QZ**, Mishiye D, Zia Z, Ruggiero RA, Aftab G. Euglycemic Diabetic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor Use Post-Bariatric Surgery: A Brief Review of the Literature. *Cureus* 2020; **12**: e10878 [PMID: 33178530 DOI: 10.7759/cureus.10878]
- 53 **Ashrafian H**, Harling L, Toma T, Athanasios C, Nikiteas N, Efthimiou E, Darzi A, Athanasios T. Type 1 Diabetes Mellitus and Bariatric Surgery: A Systematic Review and Meta-Analysis. *Obes Surg* 2016; **26**: 1697-1704 [PMID: 26694210 DOI: 10.1007/s11695-015-1999-6]
- 54 **Thawabi M**, Studyvin S. Euglycemic Diabetic Ketoacidosis, a Misleading Presentation of Diabetic Ketoacidosis. *N Am J Med Sci* 2015; **7**: 291-294 [PMID: 26199928 DOI: 10.4103/1947-2714.157490]
- 55 **Abu-Abad Abdin A**, Hamza M, Khan MS, Ahmed A. Euglycemic Diabetic Ketoacidosis in a Patient with Cocaine Intoxication. *Case Rep Crit Care* 2016; **2016**: 4275651 [PMID: 27579186 DOI: 10.1155/2016/4275651]
- 56 **Rawla P**, Vellipuram AR, Bandaru SS, Pradeep Raj J. Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma. *Endocrinol Diabetes Metab Case Rep* 2017; **2017** [PMID: 28924481 DOI: 10.1530/EDM-17-0081]
- 57 **Legaspi R**, Narciso P. Euglycemic Diabetic Ketoacidosis Due to Gastroparesis, A Local Experience. *J Ark Med Soc* 2015; **112**: 62-63 [PMID: 26390536]

- 58 **Suzuki K**, Tamai Y, Urade S, Ino K, Sugawara Y, Katayama N, Hoshino T. Alcoholic ketoacidosis that developed with a hypoglycemic attack after eating a high-fat meal. *Acute Med Surg* 2014; **1**: 109-114 [PMID: [29930832](#) DOI: [10.1002/ams2.13](#)]
- 59 **McGuire LC**, Cruickshank AM, Munro PT. Alcoholic ketoacidosis. *Emerg Med J* 2006; **23**: 417-420 [PMID: [16714496](#) DOI: [10.1136/emj.2004.017590](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

